DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Apabetalone
Apabetalone
(RVX-208) in Ex Vivo Treated Human Whole Blood and Primary Hepatocytes
Apabetalone and Hospitalization for Heart Failure in Patients Following an Acute Coronary Syndrome: a Prespecifed Analysis of the Betonmace Study Stephen J
Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response in Vitro, in Mice and in Patients with Cardiovascular Disease
Bromodomain Proteins Regulate Human Cytomegalovirus Latency and Reactivation Allowing Epigenetic Therapeutic Intervention
The Potential Rationale for BET Inhibition in Management of CVD
Effects of the Bet-Inhibitor Apabetalone On
December 22, 2020 – AGM Presentation Forward Looking Statement
Apabetalone, a Selective Bromodomain and Extraterminal
RVX-208), Reduces ACE2
The BRD4 Inhibitor Apabetalone (RVX-208) Improves Experimental PAH in Sugen/Hypoxia Rat Model
Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate SARS-Cov-2 Viral Entry
Relevance of BET Family Proteins in SARS-Cov-2 Infection
Relation of Insulin Treatment for Type 2 Diabetes to the Risk of Major
Article Effect of Apabetalone on Cardiovascular Events in Diabetes
Views Nephrology, Nephrology Dialysis Transplantation, Renal Supplemental Summary 1
Vascular Calcification
Achieving Clinical Success with BET Inhibitors As Anti-Cancer Agents
Literature Update Week 35 (2018)
Top View
Literature Update Week 28 (2019)
Apabetalone on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Diabetes Results of the Betonmace Trial
Cardiovascular Evaluation of the Selective BET Inhibitor Apabetalone in ACS Patients with Diabetes: Baseline Characteristics of the Betonmace CV Outcomes Study
13Th Clinical Trials on Alzheimer's Disease (CTAD) November 4-7, 2020
Apabetalone and Hospitalization for Heart Failure in Patients Following an Acute Coronary Syndrome: a Prespecified Analysis of the Betonmace Study
Reduces Vascular Inflammation in Vitro and in CVD Patients by a BET-Dependent Epigenetic Mechanism Laura M
(BET) Inhibitor Apabetalone: Discovery to Phase 3 Cardiovascular Outcomes Study
Article Effect of Apabetalone on Cardiovascular Events in Diabetes
Apabetalone (RVX-208)
Apabetalone (RVX-208) Reduces Vascular Inflammation in Vitro and in CVD Patients by a BET-Dependent Epigenetic Mechanism
Apabetalone (RVX-208)
Apabetalone (RVX-208) Attenuates Inflammatory Milieu Underlying Adhesion of Monocytes to Endothelial Cells in T2DM with CVD Patients Laura M
Roles of Reconstituted High-Density Lipoprotein Nanoparticles in Cardiovascular Disease: a New Paradigm for Drug Discovery
Effect of Apabetalone Added to Standard Therapy on Major
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection in Vitro
Apabetalone (RVX-208) Has Anti-Atherosclerotic, Anti-Thrombotic and Anti-Inflammatory Effects in Patients with Cardiovascular Disease